Skip to main content
OpenTrials

Clinical trial condition

Lymphoproliferative Disorders

Explore clinical trials studying Lymphoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,121 public trials 2,033 recruiting studies
Refine in advanced search Browse all conditions

Lymphoproliferative Disorders trial results

Completed

Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma

NCT02232516

Conditions
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, +32 more
Locations
  • City of Hope Duarte, California, United States
  • Yale University New Haven, Connecticut, United States
  • Northwestern University Chicago, Illinois, United States
  • Weill Cornell Medicine New York, United States
View Trial Details
Completed

Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma

NCT02332850

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +16 more
Locations
  • University of California, San Francisco San Francisco, California, United States
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • Hackensack University Medical Center Hackensack, New Jersey, United States
  • Icahn School of Medicine at Mount Sinai New York, United States
View Trial Details
Completed

Evaluating Different Doses of Orelabrutinib in MCL

NCT05978739

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations
  • The First Affiliated Hospital of Bengbu Medical College Bengbu, Anhui, China
  • The First Affiliated Hospital of Anhui Medical University Hefei, Anhui, China
  • Peking University Third Hospital Beijing, Beijing Municipality, China
  • Chongqing Cancer Hospital Chongqing, Chongqing Municipality, China
View all 20 locations
View Trial Details
Completed

Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL)

NCT04833114

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +10 more
Locations
  • UK Graz Universitätsklinik für Innere Medizin Klinische Abteilung für Hämatologie Graz, Austria
  • LKH Hochsteiermark Standort Leoben Abteilung für Innere Medizin Department für Hämato-Onkologie Leoben, Austria
  • Ordensklinikum Linz GmbH- Elisabethinen: I. Interne Abteilung Hämato-Onkologie Linz, Austria
  • Kepler Universitätsklinikum Med Campus III, Univ.-Klinik für Hämatologie und Internistische Onkologie Linz, Austria
View all 64 locations
View Trial Details
Completed

Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell Lymphoma

NCT02242097

Conditions
Contiguous Stage II Mantle Cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +12 more
Locations
  • Northwestern University Chicago, Illinois, United States
  • Northwestern University- Lake Forest Hospital Lake Forest, Illinois, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • Cleveland Clinic Cleveland, Ohio, United States
View Trial Details
Completed

A Study to Evaluate ICP-022 in Patients With R/R Mantle Cell Lymphoma (MCL)

NCT03494179

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations
  • Anhui Province Cancer Hospital Hefei, Anhui, China
  • Peking University Third Hospital Beijing, Beijing Municipality, China
  • Peking Union Medical College Hospital Beijing, Beijing Municipality, China
  • Beijing Cancer Hospital Beijing, Beijing Municipality, China
View all 31 locations
View Trial Details

Related conditions